Evidence map›Paper›PMID 36098250›Full record

ArticleBritish journal of pharmacology2023

P2X7 receptor activation impairs antitumour activity of natural killer cells.

Alberto Baroja-Mazo, Alejandro Peñín-Franch, Fernando Lucas-Ruiz, Carlos de Torre-Minguela, Cristina Alarcón-Vila, Trinidad Hernández-Caselles, Pablo Pelegrín

Open access · hybridAbstract read
In one paragraph

Article in British journal of pharmacology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 18 citations in OpenAlex.

  1. Review
  2. Genetic Deletion of the Purinergic ReceptorACS pharmacology & translational science · 2025
    Article
  3. Tumor hypoxia shapes natural killer cell anticancer activities.Journal of molecular medicine (Berlin, Germany) · 2025
    Review
  4. Review
  5. Review
  6. Article
  7. Hypoxic tumor microenvironment: Destroyer of natural killer cell function.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2024
    Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Alberto Baroja-MazoBiomedical Research Institute of Murcia (IMIB-Pascual Parrilla), University Clinical Hospital Virgen de la Arrixaca, Murcia, Spain.ORCID https://orcid.org/0000-0001-5212-5006
Alejandro Peñín-FranchBiomedical Research Institute of Murcia (IMIB-Pascual Parrilla), University Clinical Hospital Virgen de la Arrixaca, Murcia, Spain.
Fernando Lucas-RuizBiomedical Research Institute of Murcia (IMIB-Pascual Parrilla), University Clinical Hospital Virgen de la Arrixaca, Murcia, Spain.
Carlos de Torre-MinguelaBiomedical Research Institute of Murcia (IMIB-Pascual Parrilla), University Clinical Hospital Virgen de la Arrixaca, Murcia, Spain.
Cristina Alarcón-VilaBiomedical Research Institute of Murcia (IMIB-Pascual Parrilla), University Clinical Hospital Virgen de la Arrixaca, Murcia, Spain.
Trinidad Hernández-CasellesBiomedical Research Institute of Murcia (IMIB-Pascual Parrilla), University Clinical Hospital Virgen de la Arrixaca, Murcia, Spain.
Pablo PelegrínBiomedical Research Institute of Murcia (IMIB-Pascual Parrilla), University Clinical Hospital Virgen de la Arrixaca, Murcia, Spain.
Instituto Murciano de Investigación Biosanitaria · ES

Funding

European Research Council ERC-2019-PoC 899636European Union's Horizon 2020 965196Fundación Mutua Madrileña AP171362019Fundación Séneca 0003/COVI/20Fundación Séneca 20859/PI/18Fundación Séneca 21081/PDC/19Fundación Séneca 21373/PDGI/20Fundación Séneca 21655/PDC/21Instituto de Salud Carlos III DTS21/00080Instituto de Salud Carlos III PI20/00185MCIN/AEI PID2020-116709RB-I00
6 · The paper itself

Abstract

background and purposeA high number of intratumoural infiltrating natural killer (NK) cells is associated with better survival in several types of cancer, constituting an important first line of defence against tumours. Hypoxia in the core of solid tumours induces cellular stress and ATP release into the extracellular space where it triggers purinergic receptor activation on tumour-associated immune cells. The aim of this study was to assess whether activation of the purinergic receptor P2X7 by extracellular ATP plays a role in the NK cells antitumour activity. EXPERIMENTAL APPROACH: We carried out in vitro experiments using purified human NK cells triggered through P2X7 by extracellular ATP. NK cell killing activity against the tumour target cells K562 was studied by means of NK cytotoxicity assays. Likewise, we designed a subcutaneous solid tumour in vivo mouse model. KEY

resultsIn this study we found that human NK cells, expressing a functional plasma membrane P2X7, acquired an anergic state after ATP treatment, which impaired their antitumour activity and decreased IFN-γ secretion. This effect was reversed by specific P2X7 antagonists and pretreatment with either IL-2 or IL-15. Furthermore, genetic P2rx7 knockdown resulted in improved control of tumour size by NK cells. In addition, IL-2 therapy restored the ability of NK cells to diminish the size of tumours. CONCLUSIONS AND IMPLICATIONS: Our results show that P2X7 activation represents a new mechanism whereby NK cells may lose antitumour effectiveness, opening the possibility of generating modified NK cells lacking P2X7 but with improved antitumour capacity.

Indexed as

Killer Cells, NaturalNeoplasmsReceptors, Purinergic P2X7Adenosine TriphosphateAnimalsHumansInterleukin-2MiceAdenosine TriphosphateInterleukin-2Receptors, Purinergic P2X7A438079ATPIL-2natural killer cellsP2X7tumour environment

Identifiers

PMID36098250
PMCPMC10092446
OpenAlexW4295346599

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.